Akari Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Akari Therapeutics generated cash of -$16,432,000, which is more than the previous year. Cash used in financing activities reached the amount of $7,020,000 last year. Net change in cash is therefore -$9,405,000.
Cash Flow
| 2014 | -9.46M | -199K | 8.21M |
|---|---|---|---|
| 2015 | -4.96M | 1.39M | 69.04M |
| 2016 | -24.62M | -10.06M | 0 |
| 2017 | -31.59M | 9.98M | 15.67M |
| 2018 | -22.53M | 0 | 306K |
| 2019 | -12.25M | 0 | 11.98M |
| 2020 | -16.95M | 0 | 25.07M |
| 2021 | -18.84M | 0 | 14.29M |
| 2022 | -21.50M | 0 | 25.28M |
| 2023 | -16.43M | 0 | 7.02M |
AKTX Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 13.25M | 9.36M | 14.05M | 5.73M | 5.96M | 28.24M | 34.09M | 68.91M | 3.32M | 7.65M |
Operating activities | ||||||||||
Net income | -10.00M | -17.74M | -17.42M | -20.45M | -24.75M | -23.5M | -35.39M | -18.14M | -45.31M | -9.64M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 4K | 3.70K | 4.12K | 8K | 18K | 39K | 42.4K | 39.94K | 10.16K | 8K |
Stock-based compensation expense | 1.15M | 735K | 314.65K | 325.52K | 1.04M | 0 | 2.73M | 3.93M | 1.78M | 468K |
| Deferred income tax benefit | 1.15M | 735K | 314.65K | 325.52K | 1.04M | 0 | 2.73M | 3.93M | 1.78M | 468K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | 1.69M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 102K |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -223K |
Accounts payable | 0 | 0 | -241.30K | 0 | 2.38M | -3.68M | 12.22K | -671.78K | 3.75B | 351K |
Cash generated by operating activities | -16.43M | -21.50M | -18.84M | -16.95M | -12.25M | -22.53M | -31.59M | -24.62M | -4.96M | -9.46M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -46.12M | 0 | -142K |
Investments In Property Plant And Equipment | 0 | 0 | 0 | 0 | 0 | 0 | -36.88K | -54.75K | -10.56K | -57K |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.41M | 0 |
Cash generated by investing activities | 0 | 0 | 0 | 0 | 0 | 0 | 9.98M | -10.06M | 1.39M | -199K |
Financing activities | ||||||||||
Common Stock Issued | 7.02M | 25.19M | 14.29M | 25.91M | 12.64M | 891K | 15.67M | 0 | 75M | 8.21M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 7.02M | 25.28M | 14.29M | 25.07M | 11.98M | 306K | 15.67M | 0 | 69.04M | 8.21M |
Net Change In Cash | -9.40M | 3.88M | -4.69M | 8.32M | -236K | -22.28M | -5.99M | -34.82M | 65.59M | -1.44M |
Cash at end of period | 3.84M | 13.24M | 9.36M | 14.05M | 5.73M | 5.96M | 28.10M | 34.09M | 68.91M | 6.21M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |